Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors
-
Published:2022-10
Issue:10
Volume:40
Page:454.e9-454.e16
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
Miron Benjamin,
Handorf Elizabeth,
Zarrabi Kevin,
Zibelman Matthew R.,
Anari Fern,
Ghatalia Pooja,
Plimack Elizabeth R.,
Geynisman Daniel M.ORCID
Reference38 articles.
1. National Comprehensive Cancer Network. Bladder Cancer (Version 5.2021). Accessed November 14, 2021. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
2. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort†: under the auspices of the EAU-ESMO guidelines committees;Witjes;Eur Urol,2020
3. Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
4. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours;Sternberg;Eur J Cancer,2006
5. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献